ABSTRACT Purpose. The optimal dosage and frequency of platinumbased chemoradiotherapy (CRT) regimen for treating advanced head and neck squamous cell carcinoma remains unresolved. This study aims to compare the toxicity and efficacy of weekly versus more dose-intensive cisplatinbased CRTs. Methods. We reviewed 155 stage III/IV head and neck squamous cell carcinoma patients with no evidence of distant metastasis treated with one of two CRT regimens from 2000 to 2010 at Greater Baltimore Medical Center. Twicedaily radiation was provided as a split course over a 45-day period. Regimen A consisted of concomitant cisplatin (30 mg/m 2 /1 h) weekly for 6 cycles; regimen B consisted of concomitant cisplatin (12 mg/m 2 /1 h) and 5-fluorouracil (600 mg/m 2 /20 h) on days 1 through 5 and days 29 through 33. Main outcome measures included acute toxicities (myelosuppression, neurotoxicity, nephrotoxicity, gastrointestinal dysfunction), unplanned hospitalizations, and disease control at 12 months.
ABSTRACT Purpose. The optimal dosage and frequency of platinumbased chemoradiotherapy (CRT) regimen for treating advanced head and neck squamous cell carcinoma remains unresolved. This study aims to compare the toxicity and efficacy of weekly versus more dose-intensive cisplatinbased CRTs. Methods. We reviewed 155 stage III/IV head and neck squamous cell carcinoma patients with no evidence of distant metastasis treated with one of two CRT regimens from 2000 to 2010 at Greater Baltimore Medical Center. Twicedaily radiation was provided as a split course over a 45-day period. Regimen A consisted of concomitant cisplatin (30 mg/m 2 /1 h) weekly for 6 cycles; regimen B consisted of concomitant cisplatin (12 mg/m 2 /1 h) and 5-fluorouracil (600 mg/m 2 /20 h) on days 1 through 5 and days 29 through 33. Main outcome measures included acute toxicities (myelosuppression, neurotoxicity, nephrotoxicity, gastrointestinal dysfunction), unplanned hospitalizations, and disease control at 12 months.
Results. Patients on regimen A were much less likely to experience ototoxicity due to their treatment (0% vs. 9.8%, P = 0.04). They were more likely to experience thrombocytopenia acutely (46% vs. 26%, P = 0.02), but the toxicity was not limiting (grade [1] [2] . No significant differences exist in the incidence of other toxicities or unplanned hospitalizations. At 1 year, 97% of patients on A vs. 86% of patients on regimen B were free of disease (P = 0.11). Conclusions. With concurrent radiotherapy, low-dose, single-agent, weekly cisplatin is less likely than higherdose daily cisplatin plus 5-fluorouracil provided at the beginning and end of treatment to be associated with ototoxicity. The preliminary data suggest at least equivalent efficacy, but longer follow-up is required.
Concurrent chemoradiotherapy (CRT) has been established as an option for the definitive treatment of patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC). Although previous studies have shown that platinum-based CRT provides better survival than radiotherapy (RT) alone and than non-platinum-based CRT, a full-dose, single-agent cisplatin regimen is often associated with marked toxicity. chemotherapeutic agents such as cisplatin are nephrotoxicity and neurotoxicity, including peripheral neuropathy and ototoxicity. Cisplatin-related ototoxicity is characterized by a dose-dependent, high-frequency sensorineural hearing loss with tinnitus. 7 Manifestations of cisplatin nephrotoxicity include renal impairment, hypomagnesemia, salt wasting, a Fanconi-like syndrome, and anemia. 5-Fluorouracil (5-FU) may cause myelosuppression, gastrointestinal toxicity, and skin toxicity. 8 In addition to chemotherapy, RT is also associated with acute toxicities. During RT for head and neck cancer, acute reactions such as mucositis, xerostomia, dysphagia, weight loss, and dermatitis are likely to occur. RT to the normal cochlea or cranial nerve VIII can also cause sensorineural hearing loss. 9 Importantly, concurrent CRT with cisplatin may cause synergistic ototoxicity, particularly in the highfrequency range. 9 Several interventions have been introduced to reduce radiation-associated toxicity. Surgical transfer of a submandibular salivary gland to the submental space outside of the radiation field before the start of treatment has been shown to improve xerostomia. 10, 11 Moreover, parotid gland-sparing RT has been shown to result in less severe xerostomia over time. [12] [13] [14] In an effort to reduce toxicities, many different CRT regimens have been applied. Although platinum-based CRT offers better survival, the efficacy and toxicity of weekly versus more dose-intensive platinum-based regimens are unresolved. The objective of this study was to compare the toxicity and efficacy of two different cisplatinbased regimens in the primary treatment of patients with advanced HNSCC.
MATERIALS AND METHODS
Demographic and clinicopathologic parameters, including age, gender, race, smoking and alcohol history, tumor stage and grade, tumor human papillomavirus (HPV) status, and clinical outcomes data, were obtained from charts and electronic medical record. Smoking history was recorded as a binary variable, with a positive history equal to any history of tobacco use. A history of alcohol use was recorded as a binary variable with a positive history equal to any history of more than social use by the patient. The principle outcome measures of this study were short-term disease control at 12 months, acute toxicities (myelosuppression, neurotoxicity, nephrotoxicity, gastrointestinal dysfunction), and unplanned hospitalizations related to treatment.
Patient Population and Eligibility Criteria
We reviewed records of all patients newly diagnosed with HNSCC treated with one of two cisplatin-based concurrent chemoradiation regimens at the Greater Baltimore Medical Center (GBMC) from 2000 to 2010. The retrospective review of patient records was approved by the GBMC institutional review board (GBMC IRB 10-039-06). Eligible patients had either stage III or IV disease, with no evidence of distant metastases. Patients were evaluated by a multidisciplinary team consisting of head and neck surgeons, radiation oncologists, medical oncologists, speech language pathologists, nurses, and dieticians. Patients were staged according to current recommendations of the American Joint Committee on Cancer. Patients who were excluded from this study had cancers of the salivary glands and sinuses, recurrent tumors, unknown primary disease, previous CRT treatment to the head and neck, CRT regimen that was not completed, or a CRT regimen that was modified during treatment.
CRT Regimens
Both chemoradiation regimens in this study consisted of hyperfractionated irradiation of 125 cGy twice a day (6 h apart) for 28 days in a split course. A total dose of 7000 to 7500 cGy was targeted to the primary tumor site; 6000 cGy was targeted to involved lymph nodes; 5000 cGy was targeted to uninvolved lymph nodes. A treatment break of 1 week was included after 4000 cGy was provided. In regimen A, concomitant cisplatin (30 mg/m 2 ) was provided weekly for 6 cycles. Intensity-modulated radiotherapy (IMRT) was used to deliver radiation in regimen A. In addition, patients in regimen A with oropharyngeal cancers received contralateral submandibular gland transfer preceding their treatment. In regimen B, concomitant cisplatin (12 mg/m 2 /1 h) and 5-FU (600 mg/m 2 /20 h) were provided on days 1 through 5 and 29 through 33.
Evaluation of Acute Toxicity
Serum hemoglobin, platelet, and neutrophil levels were obtained from laboratory tests routinely ordered during CRT and at follow-up visits after treatment. Abnormal serum hemoglobin, platelet, and neutrophil values were graded according to the National Cancer Institute Common Toxicity Criteria to assess for severity of anemia, thrombocytopenia, and neutropenia, respectively. Serum creatinine levels were also obtained from laboratory tests routinely ordered during CRT and at follow-up visits after treatment. Abnormal serum creatinine was graded according to the National Cancer Institute Common Toxicity Criteria to assess for severity of nephrotoxicity. Otoxicity and peripheral neuropathy were evaluated at routine office visits during CRT treatment and at follow-up visits. Mucositis severity during and after treatment was scored according to the World Health Organization Oral Toxicity Scale. Percutaneous endoscopic gastrostomy (PEG) tube dependence was calculated from a patient's end of treatment date to tube removal date. Patients who had recurrent disease were censored from this calculation.
Evidence of Disease Assessment
Assessment of clinical response to CRT was made by physical examination of the primary tumor and neck nodes and CT or PET/CT scans. Most patients underwent a PET/ CT scan eight to twelve weeks after completion of CRT. Viable carcinoma was determined in lymph nodes obtained during planned neck dissection. Most patients received planned neck dissection 8-10 weeks after CRT treatment. After neck dissection, patients were expected to return for follow-up evaluation every 2-3 months in the first 2 years. All patients had a minimum of 1 year follow-up. No evidence of disease is defined as no local, regional, or locoregional recurrence, no distant metastasis, and no second primary cancer in the head and neck region.
Statistical Analysis
The Fisher's exact test or the Chi-square test was used to compare toxicity outcomes and new cancer incidence between the two chemoradiation regimens. Logistic regression was used to estimate the effects of factors on dichotomous outcomes. 15 LogXact software was used when small sample size required an exact method for estimating the odds ratio. All statistical computations were performed by SAS, LogXact, or R software. All P values reported are two sided.
RESULTS

General
One hundred sixty-one patients with HNSCC received one cisplatin-based CRT regimen at the Greater Baltimore Medical Center from 2000 to the present; 155 met the inclusion criteria and comprised our study cohort. Of these patients, 129 (83%) were men and 26 (17%) were women. The average age of patients entering the study was 59.0 years.
Fifty patients were on regimen A and 105 patients were on regimen B. For these groups, we considered the demographic and clinicopathologic characteristics of age at diagnosis, gender, race, tobacco history, smoking history, Karnofsky Performance Status, tumor site, tumor stage, tumor grade, and nodal status. With regards to these characteristics, there were no statistically significant difference between patients on regimen A and patients on regimen B (Table 1) . Regimen A had a statistically significant greater proportion of patients with positive HPV status (83.3% vs. 55.6%, P = 0.04).
Myelosuppression
We examined the incidence of acute toxicity in our study cohort from the beginning of their CRT treatment to 4 weeks after treatment for those patients with complete data. Patients on regimen A were more likely than patients on regimen B to experience thrombocytopenia (odds ratio 2.41, 95% confidence interval 1.14-5.14, P = 0.02); 46% (22 of 48) of patients on regimen A experienced acute thrombocytopenia compared to 26% (21 of 81) of patients on regimen B (Table 2) . However, the majority of thrombocytopenia experienced (90.0%) was less than grade 2 in severity and therefore not limiting (Table 3 ). There was no association between the type of regimen and severity of thrombocytopenia experienced (Table 3) . Likewise, there was no association between type of regimen and incidence of anemia or neutropenia (Table 2) , and no association between type of regimen and severity of anemia and neutropenia experienced (Table 3) .
Neurotoxicity
We also evaluated the impact of regimen on the incidence of neurotoxicity of our cohort from the beginning of their CRT treatment to 4 weeks after treatment. Patients on regimen A were much less likely than patients on regimen B to experience ototoxicity (odds ratio 0.14, 95% confidence interval -Inf to 0.95, P = 0.04). No patients on regimen A compared to 9.8% of patients on regimen B experienced ototoxicity within the first year after treatment.
There was no apparent association between type of regimen and incidence of peripheral neuropathy (Table 2 ).
Nephrotoxicity
We examined the incidence of nephrotoxicity in our study cohort from the beginning of their CRT treatment to 4 weeks after treatment. There was no association between the type of regimen and incidence of nephrotoxicity (21% on regimen A vs. 12% on regimen B, P = 0.18) ( Table 2 ). The two regimens also did not differ significantly in the severity of nephrotoxicity experienced; 4.2% of patients on regimen A vs. 3.6% of patients on regimen B experienced greater than or equal to grade 2 nephrotoxicity (P = 0.87) ( Table 3) .
Gastrointestinal Dysfunction
To assess the impact of regimen type on gastrointestinal dysfunction, we examined the incidence of severe mucositis, stricture, and prolonged PEG tube dependence in our study cohort. There was no association between type of regimen and incidence of severe mucositis. Twenty-six percent of patients on regimen A compared to 34% patients on regimen B experienced grade 3 mucositis. Sixty-five percent of patients on regimen A compared to 60% of patients on regimen B experienced grade 4 mucositis (P = 0.59) ( Table 3) .
There was also no association between type of regimen and incidence of stricture requiring dilation procedure (22% on regimen A vs. 20% on regimen B, P = 0.77) during and after treatment ( Table 2 ).
All patients in both regimen A and B received prophylactic PEG tubes in anticipation of their treatment. On average, patients on regimen A remained with their PEG tube for 158.9 days after treatment, while patients on regimen B remained with their PEG tube for 202.2 days after treatment (P = 0.35). Twenty-four percent of patients on regimen A compared to 36% of patients on regimen B were PEG tube dependent at 6 months after treatment (P = 0.27) ( Table 2) . Three percent of patients on regimen A compared to 9% of patients on regimen B were PEG tube dependent at 12 months after treatment (P = 0.34) ( Table 2) . Patients who had disease recurrence within the first year after treatment were excluded from the calculations.
Hospitalization
Overall, 26% of patients on regimen A compared to 21% of patients on regimen B had unplanned hospitalizations related to their treatment (P = 0.48). On average, each hospitalization was 8.0 days for patients on regimen A and 14.2 days for patients on regimen B. There was no significant difference between regimen type and reason for hospitalization (gastrointestinal, sepsis/fever, renal, hematologic, pulmonary, cardiovascular) ( Table 4) .
Short-term Disease Control
At 12 months after treatment, 97% of patients on regimen A compared to 86% of patients on regimen B had no evidence of disease at their follow-up visit (P = 0.11). When we examined short-term disease control by HPV status in patients with oropharyngeal cancer, we saw no statistically significant difference in the incidence of a disease-free state at 12 months after treatment between the HPV-negative and HPV-positive groups (84% of HPVnegative group vs. 94% of HPV-positive group, P = 0.33).
Overall, regimen A had a statistically significant greater proportion of patients with positive HPV status (83.3 vs. 55.6%, P = 0.04). HPV-negative patients were more likely than HPV-positive patients to have unplanned hospitalizations during treatment (43.5 vs 20.0%, P = 0.05). However, when we examined the incidence of acute toxicity from the beginning of their treatment to 4 weeks after treatment by HPV status in patients with oropharyngeal cancer, we saw no statistically significant difference in acute toxicities between the HPV-negative and HPVpositive groups. There was also no association between HPV status and disease control at 12 months after treatment (Table 5) .
DISCUSSION
The use of CRT for the management of HNSCC aims to provide effective primary treatment, while reducing both disease and treatment-associated morbidity. Previous studies have shown platinum-based CRT to provide better survival to both definitive RT alone and non-platinumbased CRT regimens. 16 However, within definitive CRT paradigms, efficacy and toxicity of weekly low-dose versus daily dose-intensive platinum-based CRT regimens remain unresolved. Large single-institutional reviews, in which the toxicity and efficacy of weekly cisplatin-based CRT versus more dose-intensive cisplatin-based CRT are directly compared in a group of highly compliant HNSCC patients, are limited.
Full-dose, single-agent cisplatin is associated with significant toxicities. [1] [2] [3] [4] The main unique side effects of platinum-based chemotherapeutic agents such as cisplatin are neurotoxicity, ototoxicity, and nephrotoxicity. In singleand multi-institutional randomized studies, concurrent, platinum-based CRT regimens with reduced platinum dose, increased frequency, and/or added complementary chemotherapeutic agent have been shown to be tolerable. [16] [17] [18] [19] [20] [21] [22] [23] Regimen A involved a lower-dose weekly cisplatin than regimen B and had no 5-FU. Thus, it was expected to be associated with lower incidence of acute toxicities. We found the incidence of anemia, neutropenia, nephrotoxicity, peripheral neuropathy, and unplanned hospitalizations due to treatment related morbidity to be similar between the two regimens. However, we observed a significantly lower incidence of ototoxicity with the low-dose, single-agent, weekly cisplatin-based CRT regimen. Cisplatin-related ototoxicity is characterized by a dose-dependent, high frequency sensorineural hearing loss with tinnitus. 7 Lowering the incidence of this irreversible hearing loss is important for providing effective treatment that also preserves patient quality of life. The mean age was 59 years for both cohorts in our group. Therefore, it is unlikely that the difference in ototoxicity incidence can be explained by treatment-independent age-related hearing loss. Another factor worth considering is the differences between the two regimens in terms of the radiation delivery method. More specifically, although the RT used in group A was IMRT, that was not the case with the RT used in group B. One might wonder if the lower incidence of ototoxicity in group A was merely a result of decreased radiation dosing to the cochlear with IMRT. This possibility seems to be further supported by the fact that we saw equal levels of peripheral neuropathy outside the radiation field. Previous studies have demonstrated that IMRT can result in excellent local disease control while delivering a low mean dose of radiation to the cochlear and resulting in a low rate of ototoxicity. 24 Interestingly, some studies have suggested that there are no significant differences in average radiation dose in ears with sensorineural threshold deterioration and those without after receiving RT for nasopharyngeal carcinoma. 25 A recent review of literature by Bhandare et al. on the development of sensorineural hearing loss after high-dose RT for HNC concluded that a specific threshold dose to cochlea for sensorineural hearing loss cannot be determined on the basis of current data; however, they suggested dose-prescription limits: For conventionally fractionated RT, to minimize the risk for SNHL, the mean dose to the cochlea should be limited to B45 Gy (or more conservatively B35 Gy). 26 In our study, the mean radiation dose to the cochlea was similar between the two regimens and was well below the conservative dose suggested by Bhandare et al. (the mean dose to the cochlea via IMRT in group A was 11.37 Gy; the mean dose to the cochlea in group B was 13.26 Gy).
Overall, there was no significant difference between the regimens in the incidence of grade 3-4 thrombocytopenia. However, we did observe that low-dose weekly cisplatinbased CRT was associated with higher overall incidence of acute thrombocytopenia. One might expect combination chemotherapy to have higher risks of developing hematologic toxicity than single agent chemotherapy. However, the weekly nature of chemotherapy administration likely contributed to a higher incidence of acute thrombocytopenia than the regimen with daily 5-FU and higher dose cisplatin during the first and last week of CRT. Myelosuppression associated with CRT is usually selflimited, as was the case in this study. Regimen A differed from regimen B in providing patients with oropharyngeal cancers with submandibular gland transfer before radiation, and in the use of IMRT to deliver radiation. Studies have shown that up to 100 percent of patients undergoing RT for the oropharynx or oral cavity experience xerostomia to some extent. 27 Decreased saliva results in change in taste function and decreased oral intake of food. Because radiation of the oropharynx can lead to mucosal inflammation, edema, fibrosis, pharyngeal stenosis, and soft tissue necrosis, particularly when radiation is provided with chemotherapeutic agents, partial or total esophageal stricture may occur. Surgical transfer of a submandibular salivary gland to the submental space outside of the radiation field before the start of treatment has been shown to improve xerostomia. 10, 11 Moreover, conformal RT techniques in treatment planning and delivery, such as IMRT, can spare the contralateral parotid gland and result in less xerostomia. [28] [29] [30] [31] [32] [33] [34] [35] We saw that, with the use of submandibular gland transfer and IMRT in regimen A, the incidence of PEG tube dependence was lower for patients in regimen A at 6 months (24.1% vs. 35.5%, P = 0.27) and at 12 months (3.4% vs. 9.2%, P = 0.34), though this did not reach statistical significance.
In addition to hydrating with fluids and gargling with a weak salt solution to ameliorate xerostomia, pharmacologic agents, such as amifostine, have been suggested. Amifostine has been shown to effectively improve xerostomia associated with RT. 36 It has also been shown to improve xerostomia in patients receiving CRT. [37] [38] [39] Importantly, despite concerns about reduced RT efficacy with the use of amifostine, several studies have shown that amifostine treatment does not affect the clinical outcome and effectiveness of CRT. 37, 38, 40 However, the benefit of amifostine is limited by the inconvenience and cost of its daily infusions. A potential alternative is administering amifostine subcutaneously instead of intravenously. Subcutaneous amifostine has been suggested to provide similar protection, better toleration, reduced cost, and more convenience than intravenous amifostine. 41, 42 ASCO guidelines currently recommend that amifostine be considered for the reduction of xerostomia in patients receiving RT. 40 The retrospective nature of this study introduces some limitations. Despite our incorporation of the major demographic and clinicopathologic characteristics that are most likely to affect outcomes, such as HPV status, tumor stage, nodal involvement, smoking history, and alcohol history, other factors may still confound our results. However, because these patients were treated in a single center with a common approach, many of the possible treatment variables have been controlled between the two regimens.
In conclusion, with concurrent RT, single-agent, lowdose weekly cisplatin is much less likely than higher-dose daily cisplatin plus 5-FU at the start and end of treatment to be associated with ototoxicity. Long-term feeding tube use was low in both regimens. Our 1-year surveillance data suggest that both regimens are equally effective in treating the cancers, but longer follow-up is required.
